* Says the test delivers results in 30 mins
* Says test to be marketed with Instrumentation Laboratory
* Shares up 6 pct in after-market trade
Sept 24 (Reuters) - Cepheid said the U.S. health regulator has granted marketing approval to the company's diagnostic test to detect an increased genetic risk of developing blood clots, sending its shares up 6 percent.
The company, which makes systems and tests for genetic analysis, said its Xpert HemosIL FII & FV test, detects certain genetic variations associated with thrombophilia, an increased risk of blood clot.
The test, to be marketed in partnership with Instrumentation Laboratory, delivers results in just over thirty minutes using a single GeneXpert cartridge, the company said.
Shares of the company rose 6 percent at $14.43 in after-market trade. They had closed at $13.44 Thursday on Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by Pradeep Kurup) Keywords: CEPHEID/ (shailesh.kuber@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: shailesh.kuber.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says test to be marketed with Instrumentation Laboratory
* Shares up 6 pct in after-market trade
Sept 24 (Reuters) - Cepheid said the U.S. health regulator has granted marketing approval to the company's diagnostic test to detect an increased genetic risk of developing blood clots, sending its shares up 6 percent.
The company, which makes systems and tests for genetic analysis, said its Xpert HemosIL FII & FV test, detects certain genetic variations associated with thrombophilia, an increased risk of blood clot.
The test, to be marketed in partnership with Instrumentation Laboratory, delivers results in just over thirty minutes using a single GeneXpert cartridge, the company said.
Shares of the company rose 6 percent at $14.43 in after-market trade. They had closed at $13.44 Thursday on Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by Pradeep Kurup) Keywords: CEPHEID/ (shailesh.kuber@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: shailesh.kuber.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.